Collegium Pharmaceutical Inc. (COLL)
NASDAQ: COLLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
COLL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $768.18M
- P/E (TTM)
- 22.68
- Forward P/E
- 3.49
- EPS (TTM)
- $1.09
- Dividend yield
- None
- 52-week range
- 21.43 – 50.79
- Day range
- 24.64 – 25.43
- Volume / Avg
- 528.02K / 754.45K
- Beta
- —
- Shares outstanding
- 31.08M
52-week range
COLL stock today
Shares of Collegium Pharmaceutical (COLL) finished lower on Nov 20 at $24.72, a drop of 1.94% or $0.49 per share, versus the S&P 500's 3.70% decline. At this level, COLL sits near the bottom of its 52-week range of $21.43 to $50.79: 51.3% below the high, set on Dec 29, 2025 and 15.4% above the low. COLL is down 46.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.2%.
Collegium Pharmaceutical trades at 22.7x its trailing twelve-month earnings per share of $1.09. Its forward P/E of 3.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Collegium Pharmaceutical
Company profileCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Vikram Karnani
- Headquarters
- Stoughton, MA
- Employees
- 423
- IPO year
- 2015
- Website
- collegiumpharma.com
Financial highlights
Full financialsIn fiscal 2025, Collegium Pharmaceutical generated $780.6 million in revenue, up 23.6% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $62.9 million (-9.1% year over year), for a net margin of 8.1% versus a median of 8.6% in the prior 5 years. Gross margin was 59.3% (down from 59.8%) and operating margin 23.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $780.57M | $631.45M | $566.77M | $463.93M | $276.87M |
| Growth | +23.62% | +11.41% | +22.17% | +67.56% | -10.69% |
| Net income | $62.87M | $69.19M | $48.16M | $-25.00M | $71.52M |
| EPS (diluted) | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$44.00+77.99%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.60 vs $1.53
- Surprise
- -60.78%
COLL news
All COLL news- J&J to Boost Ophthalmology Pipeline With $2.2B Ollin AcquisitionNasdaqJNJ, COLL, VCEL
- INCY Wins European Commission Nod For Skin Disease DrugNasdaqINCY, NVS, COLL
- Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HSNasdaqNVS, COLL, VCEL, KROS
- NKTR Q3 Earnings Beat Estimates, 2026 Revenue View Cut, Stock DownNasdaqNKTR, LLY, COLL
- Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity ProgramNasdaqPFE, COLL, VCEL, AMRX
- LQDA Q3 Earnings Beat Estimates on Robust Yutrepia SalesNasdaqLQDA, UTHR, COLL, AMRX
- TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock UpNasdaqTGTX, HALO, COLL, AMRX
- IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock UpNasdaqIRWD, AZN, ABBV, COLL
Collegium Pharmaceutical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs COLL |
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs COLL |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs COLL |
| ORICOric Pharmaceuticals Inc. | 7.36 | -4.42% | $764.94M | vs COLL |
| RIGLRigel Pharmaceuticals Inc. | 40.09 | -2.67% | $754.89M | vs COLL |
| ARDXArdelyx Inc. | 2.99 | -2.29% | $751.60M | vs COLL |
| CRVSCorvus Pharmaceuticals Inc. | 9.67 | -3.40% | $815.69M | vs COLL |
| IVAInventiva S.A. American Depository Shares | 3.14 | -8.99% | $750.78M | vs COLL |
Indexes, lists and sector
Collegium Pharmaceutical stock FAQ
What is Collegium Pharmaceutical's stock price today?
COLL last traded at $24.72 as of Nov 20, 4:00 PM EST, down 1.94% on the day. Prices are delayed at least 15 minutes.
What is COLL's P/E ratio?
COLL trades at a trailing P/E ratio of 22.68 and a forward P/E of 3.49.
Who is Collegium Pharmaceutical's CEO?
Mr. Vikram Karnani is the chief executive officer of Collegium Pharmaceutical Inc., which has about 423 employees.
What is the COLL 52-week high?
The 52-week high for COLL is $50.79 and the 52-week low is $21.43. The stock is currently 51.3% below its high.